PMID- 30710341
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20211204
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 234
IP  - 8
DP  - 2019 Aug
TI  - mTOR Signaling pathway as a master regulator of memory CD8(+) T-cells, Th17, and 
      NK cells development and their functional properties.
PG  - 12353-12368
LID - 10.1002/jcp.28042 [doi]
AB  - The mammalian target of rapamycin (mTOR) is a member of the evolutionary 
      phosphatidylinositol kinase-related kinases (PIKKs). mTOR plays a pivotal role in 
      the regulation of diverse aspects of cellular physiology such as body metabolism, 
      cell growth, protein synthesis, cell size, autophagy, and cell differentiation. 
      Immunologically, mTOR has a fundamental part in controlling and shaping diverse 
      functions of innate and adaptive immune cells, in particular, T-cell subsets 
      differentiation, survival, and metabolic reprogramming to ultimately regulate the 
      fate of diverse immune cell types. Researchers report that rapamycin, a selective 
      mTOR inhibitor, and immunosuppressive agent, has surprising immunostimulatory 
      effects on inducing both quantitative and qualitative aspects of virus-specific 
      memory CD8(+) T-cells differentiation and homeostasis in a T-cell-intrinsic 
      manner. The mTOR signaling pathway also plays a critical role in dictating the 
      outcome of regulatory T cells (Treg), T helper 17 (Th17) cells, and natural 
      killer (NK) cells proliferation and maturation, as well as the effector functions 
      and cytotoxic properties of NK cells. Manipulation of mTOR activity is a critical 
      therapeutic approach for pharmacological agents that seek to inhibit mTOR. This 
      approach should enhance specific memory CD8 (+) T-cells responses and induce 
      fully functional effector properties of NK cells to provoke their antitumor and 
      antiviral activities.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Rostamzadeh, Davood
AU  - Rostamzadeh D
AUID- ORCID: 0000-0002-5528-1984
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
AD  - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
FAU - Yousefi, Mehdi
AU  - Yousefi M
AUID- ORCID: 0000-0002-1144-098X
AD  - Department of Immunology, Faculty of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
AD  - Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Haghshenas, Mohammad Reza
AU  - Haghshenas MR
AD  - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of 
      Medical Sciences, Shiraz, Iran.
FAU - Ahmadi, Majid
AU  - Ahmadi M
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
AD  - Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Dolati, Sanam
AU  - Dolati S
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
AD  - Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Babaloo, Zohreh
AU  - Babaloo Z
AD  - Immunology Unit, Drug Applied Research Center, Tabriz University of Medical 
      Sciences.
AD  - Head of Immunology Department, Medicine Faculty, Tabriz University of Medical 
      Science.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190202
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - CD8-Positive T-Lymphocytes/*cytology/immunology
MH  - Cell Differentiation/drug effects/physiology
MH  - Cell Proliferation/drug effects
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology
MH  - Killer Cells, Natural/*cytology/immunology
MH  - Lymphocyte Activation/drug effects
MH  - Signal Transduction/drug effects
MH  - Sirolimus/pharmacology
MH  - T-Lymphocyte Subsets/cytology/immunology
MH  - T-Lymphocytes, Regulatory/*cytology/immunology
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
MH  - Th17 Cells/*cytology/immunology
OTO - NOTNLM
OT  - NK cell
OT  - Th17
OT  - immune responses
OT  - mTOR
OT  - memory CD8+ T-cell
OT  - regulatory T-cell
EDAT- 2019/02/03 06:00
MHDA- 2020/05/22 06:00
CRDT- 2019/02/03 06:00
PHST- 2018/10/19 00:00 [received]
PHST- 2018/12/03 00:00 [accepted]
PHST- 2019/02/03 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
PHST- 2019/02/03 06:00 [entrez]
AID - 10.1002/jcp.28042 [doi]
PST - ppublish
SO  - J Cell Physiol. 2019 Aug;234(8):12353-12368. doi: 10.1002/jcp.28042. Epub 2019 
      Feb 2.